Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

716 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of long-term intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness--Justification for Atherosclerosis Regression Treatment (JART) extension study.
Nohara R, Daida H, Hata M, Kaku K, Kawamori R, Kishimoto J, Kurabayashi M, Masuda I, Sakuma I, Yamazaki T, Yokoi H, Yoshida M; Justification For Atherosclerosis Regression Treatment (JART) Investigators. Nohara R, et al. Among authors: kurabayashi m. Circ J. 2013;77(6):1526-33. doi: 10.1253/circj.cj-12-1149. Epub 2013 Mar 14. Circ J. 2013. PMID: 23486191 Free article. Clinical Trial.
Superior benefit of aggressive lipid-lowering therapy for high- risk patients using statins: the SUBARU study--more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy.
Kurabayashi M, Yamazaki T; SUBARU Study Group. Kurabayashi M, et al. J Atheroscler Thromb. 2008 Dec;15(6):314-23. doi: 10.5551/jat.e567. Epub 2008 Dec 6. J Atheroscler Thromb. 2008. PMID: 19060425 Free article. Clinical Trial.
Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justification for Atherosclerosis Regression Treatment (JART) study.
Nohara R, Daida H, Hata M, Kaku K, Kawamori R, Kishimoto J, Kurabayashi M, Masuda I, Sakuma I, Yamazaki T, Yokoi H, Yoshida M; Justification for Atherosclerosis Regression Treatment (JART) Investigators. Nohara R, et al. Among authors: kurabayashi m. Circ J. 2012;76(1):221-9. doi: 10.1253/circj.cj-11-0887. Epub 2011 Nov 16. Circ J. 2012. PMID: 22094911 Free article. Clinical Trial.
Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study.
Yamazaki T, Nohara R, Daida H, Hata M, Kaku K, Kawamori R, Kishimoto J, Kurabayashi M, Masuda I, Sakuma I, Yokoi H, Yoshida M; Justification for Atherosclerosis Regression Treatment (JART) Investigators. Yamazaki T, et al. Among authors: kurabayashi m. Int Heart J. 2013;54(1):33-9. doi: 10.1536/ihj.54.33. Int Heart J. 2013. PMID: 23428922 Free article. Clinical Trial.
716 results